All Updates

All Updates

icon
Filter
Product updates
Massive Bio launches Drug Utilization Optimizer at ASCO 2024
Clinical Trial Technology
Jun 1, 2024
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Product updates
Microsoft launches Copilot Actions for workplace automation
Foundation Models
Yesterday
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
Clinical Trial Technology

Clinical Trial Technology

Jun 1, 2024

Massive Bio launches Drug Utilization Optimizer at ASCO 2024

Product updates

  • Massive Bio, a provider of AI-driven oncology solutions, announced the launch of its latest product, the "Drug Utilization Optimizer (DUO)," at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024. The DUO platform is developed to restructure how pharmaceutical commercial teams communicate with physicians and collect data.

  • DUO provides real-time insights, identifies key physicians conducting certain diagnostic testing at the local, regional, and country levels, and enhances brand revenues while minimizing sales costs. It also enables access to clinical and genomic data for precision targeting that goes beyond traditional data sources. Additionally, DUO helps promote testing for patients who need it and provides an industry-wide network of oncology experts.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.